Companies /Healthcare

Mannkind Corp

NASDAQ: MNKD Biotechnology
$3.45
▼ $0.26 (−7.01%) today
Markets closed · 5:58pm ET

MNKD at a Glance

Valuation
Market cap
$1.2B
Profitability
Revenue (TTM)
$393.6M
Profit margin
-11.1%
EPS (TTM)
$-0.14
Price
52-week range
$2 – $7
Street target
$7.97
Earnings
Next report
Nov 4, 2026

Headquartered in Danbury, CT Fiscal year ends December NASDAQ: MNKD mannkindcorp.com

About MannKind

MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care through innovative drug-device combination therapies for cardiometabolic and orphan lung diseases. Its commercial portfolio includes Afrezza (inhaled insulin for diabetes, now approved for adults and pediatric patients ages 6+), Furoscix (subcutaneous furosemide injection for edema in heart failure and chronic kidney disease, including the newly approved ReadyFlow autoinjector), and V-Go (a wearable insulin delivery device). MannKind also generates significant revenue from collaborations with United Therapeutics, including manufacturing and royalties related to Tyvaso DPI for pulmonary hypertension. The company's development pipeline includes MNKD-201 (nintedanib dry powder inhaler for idiopathic pulmonary fibrosis, currently in Phase 2) and MNKD-1501 (ralinepag DPI for pulmonary arterial hypertension, approaching IND filing). MannKind leverages its proprietary Technosphere drug-device platform to deliver therapies via inhalation, targeting improved patient compliance and outcomes. Updated

MNKD Coverage

9:41am ET
Health and Healthcare

Big Biotechs Scare Off Short Sellers

The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.

Chris Lange
8:45am ET
Health and Healthcare

Short Sellers Wary on Major Biotechs

The January 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.

Chris Lange

Frequently Asked Questions

What does MannKind do?

MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care through innovative drug-device combination therapies for cardiometabolic and orphan lung diseases.

What is the MNKD stock price target?

The Wall Street consensus 12-month price target for MNKD is $7.97.